Search results for "Coronavirus disease"

showing 10 items of 961 documents

SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients

2020

Background The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and methods This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers wer…

0301 basic medicineMaleAntibodies ViralSeverity of Illness IndexGastroenterologylaw.invention0302 clinical medicinelaw030212 general & internal medicinebiologyInflammatory biomarkersMiddle AgedIntensive care unitHospitalizationTiterInfectious DiseasesSpike Glycoprotein CoronavirusFemaleAntibodyCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyPneumonia ViralNeutralizing antibodiesArticleVirus03 medical and health sciencesBetacoronavirusYoung AdultVirologyInternal medicineSeverity of illnessmedicineHumansPandemicsAgedRetrospective StudiesInflammationbusiness.industrySARS-CoV-2C-reactive proteinCOVID-19Retrospective cohort studyAntibodies NeutralizingFerritinbiology.proteinBinding Sites AntibodybusinessBiomarkers
researchProduct

Proper assignation of reactivation in a COVID-19 recurrence initially interpreted as a reinfection

2021

A 77-year-old-male (Case R) who had had a previous diagnosis of mild COVID-19 episode, was hospitalized 35 days later. On Day 23 post-admission, he developed a second COVID-19 episode, now severe, and finally died. Initially, Case R COVID-19 recurrence was interpreted as a reinfection due to the exposure to a SARS-CoV-2 RT-PCR-positive room-mate. However, whole-genome-sequencing indicated that case R recurrence corresponded to a reactivation of the strain involved in his first episode. Case R reactivation had major consequences, leading to a more severe episode, and causing a subsequent transmission to another two hospitalized patients, one of them with fatal outcome.

0301 basic medicineMalePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakFatal outcomeCoronavirus disease 2019 (COVID-19)Hospitalized patientsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibodies Viral03 medical and health sciences0302 clinical medicineNosocomial transmissionRecurrencemedicineImmunology and AllergyHumans030212 general & internal medicineAgedFirst episodeWhole Genome Sequencingbusiness.industrySARS-CoV-2Nosocomial transmissionBrief ReportCOVID-19Reactivation030104 developmental biologyInfectious DiseasesAcademicSubjects/MED00290ReinfectionbusinessWGS
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres.

2021

Abstract Objectives To our knowledge no previous study has assessed the performance of a rapid antigen diagnostic immunoassay (RAD) conducted at the point of care (POC). We evaluated the Panbio™ COVID-19 Ag Rapid Test Device for diagnosis of coronavirus 2019 disease (COVID-19) in symptomatic patients (n = 412) attending primary healthcare centres. Methods RAD was performed immediately after sampling following the manufacturer's instructions (reading at 15 min). RT-PCRs were carried out within 24 h of specimen collection. Samples displaying discordant results were processed for culture in Vero E6 cells. Presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cell cultures…

0301 basic medicineMaleRapid antigen detection test (RAD)medicine.disease_causeAmbulatory Care Facilities0302 clinical medicineNasopharynx030212 general & internal medicineChildAntigens ViralCoronavirusAged 80 and overImmunoassaymedicine.diagnostic_testGeneral MedicineMiddle AgedEarly diagnosisResearch NoteInfectious DiseasesSpecimen collectionRapid antigen testPoint-of-Care TestingCOVID-19 Nucleic Acid TestingChild PreschoolFemaleMicrobiology (medical)Adultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)AdolescentPoint-of-care testing030106 microbiologySensitivity and SpecificityCOVID-19 Serological Testing03 medical and health sciencesYoung AdultAntigenInternal medicinemedicineHumansPoint of careAgedbusiness.industrySARS-CoV-2COVID-19InfantImmunoassayReagent Kits DiagnosticbusinessPrimary healthcare centreClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine

2021

(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection

0301 basic medicineMedicine (General)Coronavirus disease 2019 (COVID-19)Chemiluminescence immunoassayvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical BiochemistryAsymptomaticArticleAntibodies03 medical and health sciencesR5-9200302 clinical medicineMedicineKineticMessenger RNAbiologySARS-CoV-2business.industryVaccinationvirus diseasesCOVID-19spikeVaccination030104 developmental biologyAntibody response030220 oncology & carcinogenesisImmunologybiology.proteinmedicine.symptomAntibodybusinessImmunosurvellianceVaccineS-RBD IgGDiagnostics
researchProduct

Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia.

2020

A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs …

0301 basic medicineMesenchymal stem cells coronavirus2019-20 coronavirus outbreakfunction recoveryStromal cellCoronavirus disease 2019 (COVID-19)mesenchymal stem cells COVID-19Clinical BiochemistryAdipose tissuemedicine.disease_causeimmunomodulationOrginal Articlestem cell therapy COVID-19cellular therapy COVID-1903 medical and health sciences0302 clinical medicineDrug Discoverymedicinecell transplantationMesenchymal stem cells coronavirusCoronavirusPharmacologymesenchymal stem cellsbusiness.industrymesenchymal stem cells COVID-19Settore MED/19COVID-19medicine.diseaseVirologyACE2 negativeadipose-derived stem cells coronavirusadipose-derived stem cells coronavirusPneumoniaEditorialstem cell therapy COVID-19030104 developmental biology030220 oncology & carcinogenesiscellular therapy COVID-19Functional activityStem cellbusinessExpert opinion on biological therapy
researchProduct

The usefulness of NEWS2 at day 7 of hospitalization in predicting COVID-19 evolution and as an early endpoint in therapeutic trials

2021

Highlights • There is a need for reliable tools to predict the evolution of hospitalized patients suffering from COVID-19 • The likelihood of unfavourable evolution for patients hospitalized for COVID-19 with a National • Early Warning Score 2 (NEWS2) below 7 at Day 7 of hospitalization is nearly non-existent • Such a score could thus be used to allow earlier discharge of the patients and as a judgement criterion in therapeutic trials

0301 basic medicineMicrobiology (medical)2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNEWS2Communicable DiseasesArticle03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineIntensive care medicineUnfavourable eventAgedbusiness.industrySARS-CoV-2COVID-19Therapeutic trialCoronavirusHospitalizationInfectious DiseasesItalySARS-CoV2businessPredictionThe Journal of Infection
researchProduct

Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patien…

2021

Objectives There is limited information on the performance of rapid antigen detection (RAD) tests to identify SARS-CoV-2-infected asymptomatic individuals. In this field study, we evaluated the Panbio™ COVID-19 Ag Rapid Test Device (Abbott Diagnostics, Jena, Germany) for this purpose. Methods A total of 634 individuals (355 female; median age, 37 years; range, 9–87) were enrolled. Two nasopharyngeal swabs were collected from household (n = 338) and non-household contacts (n = 296) of COVID-19 cases. RAD testing was carried out at the point of care. The RT-PCR test used was the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, MA, USA). Results Household contacts were tested at a median …

0301 basic medicineMicrobiology (medical)AdultMale2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Rapid antigen detection testAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Point-of-Care Systems030106 microbiologyTest sensitivityImmunologic TestsAsymptomaticSensitivity and Specificity03 medical and health sciencesYoung Adult0302 clinical medicineCOVID-19 TestingInternal medicineMedicineHumans030212 general & internal medicineChildAntigens ViralAsymptomatic InfectionsAgedAged 80 and overImmunoassayFamily Characteristicsbusiness.industrySARS-CoV-2COVID-19General MedicineMiddle AgedTest (assessment)AsymptomaticResearch NoteInfectious DiseasesRapid antigen testCOVID-19 Nucleic Acid TestingClose contactsFemalemedicine.symptomContact TracingbusinessContact tracingClinical Microbiology and Infection
researchProduct

Early detection of SARS-CoV-2 infection cases or outbreaks at nursing homes by targeted wastewater tracking

2021

Objectives Near-source tracking of SARS-CoV-2 RNA in the sewage drains serving particular buildings may allow rapid identification of SARS-CoV-2 infection cases or local outbreaks. In this pilot study, we investigated whether this was the case for nursing homes (NH). Methods The study involved five NH (from A to E) affiliated to the Clínico-Malvarrosa Health Department, Valencia (Spain). These were nursing or mixed nursing/care homes of different sizes, altogether providing care for 472 residents attended by a staff of 309. Near-source sewage samples were screened for presence of SARS-CoV-2 RNA by RT-qPCR at least 5 days per week during the study period. SARS-CoV-2 RNA testing in nasopharyn…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCOVID-19 outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)030106 microbiologyNursing homesEarly detectionSewageWastewater03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineSanitary sewerskin and connective tissue diseasesLetter to the EditorAgedSARS-CoV-2business.industryfungiCOVID-19OutbreakGeneral MedicineSARS-CoV-2 RNANursing Homesbody regionsInfectious DiseasesWastewaterEmergency medicineWater MicrobiologyNursing homesbusinessNear-source tracking
researchProduct

Point-of-care evaluation of a rapid antigen test (CLINITESTⓇ Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and as…

2021

AbstractRapid antigen assays (RAD) based on lateral flow immunochromatography (LFIC) technology have emerged as a valuable tool for the control of COVID-19 pandemic. Manufacturer□independent, real□world evaluation of these assays is crucial given the considerable heterogeneity reported in their clinical and analytical performances. Here, we report for the first time on the point-of-care performance of the CLINITEST® Rapid COVID-19 Antigen Test (Siemens, Healthineers, Erlangen, Germany) to detect SARS-CoV-2 infection in presumptive COVID-19 cases or asymptomatic close contacts of COVID-19 patients. When compared to RT-PCR, the overall sensitivity of the assay was 80.2 (95% CI, 70.9-87.1) for…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCopper SulfateCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Point-of-Care Systems030106 microbiologyPopulationAsymptomaticSensitivity and SpecificityCitric Acid03 medical and health sciences0302 clinical medicineInternal medicineAntigen assaysmedicineHumans030212 general & internal medicineeducationLetter to the EditorPoint of careeducation.field_of_studybusiness.industrySARS-CoV-2COVID-19Antigen testInfectious DiseasesSodium BicarbonateRapid antigen testmedicine.symptombusinessThe Journal of Infection
researchProduct